Report Date: Tuesday, August 4, 2026, before market open Event: 2026Q2 Earnings Call
Merck heads into tomorrow's print with the stock up nicely off its spring lows — shares have climbed from roughly $112 in early May to the $128–$130 range currently, a move roughly in line with the "up around 17% so far in 2026" narrative that's built up over the summer on the back of a wave of pipeline and regulatory news. Sentiment ahead of the quarter looks constructive but not exuberant: the consensus view among 28 analysts surveyed remains bullish, with 19 rating the stock a buy, and the mean price target of $135.19 implies roughly 4% upside from the current $130.20 share price.
That said, one line item will jump out at anyone glancing at the headline print: another quarterly loss. Analysts model a non-GAAP loss of roughly $0.25–$0.29 per share on revenue of about $16.3–$16.4 billion, versus a profit of $1.36 in the year-ago period — a quarterly loss of $0.26 per share, which represents a year-over-year change of -112.2%. This isn't an operating problem — it's almost entirely a function of Merck's aggressive, science-led M&A pace.
Merck's income statement has been scrambled by two large deals this year:
That's the direct explanation for why Wall Street's model shows Merck swinging to a loss even as the underlying, ex-charges business keeps growing revenue at a mid-single-digit clip. Notably, the negative results come as Merck navigates a portfolio transition beyond blockbuster cancer drug Keytruda, recently launching Lipfendra, the first oral PCSK9 inhibitor for lowering cholesterol. Investors should focus less on the reported EPS number and more on: (1) core/underlying non-GAAP trends ex-Terns, (2) whether full-year guidance is reaffirmed/raised, and (3) whether the $65.8–$67.0B sales / $5.04–$5.16 EPS framework set in Q1 (which explicitly excluded Terns) gets updated now that the deal has closed.
One yellow flag: EPS estimates have plunged 68% over the past 60 days, even as revenue estimates have held steady — a divergence that suggests margin compression or one-time charges are weighing on near-term profitability, making management's explanation for the profit trajectory the thing to listen for most closely on the call.
Merck's Q1 2026 results (reported April 30) showed: - Total sales of $16.3 billion, up 5% (3% ex-FX) - Keytruda/Keytruda Qlex sales of $8.0 billion, up 12% (8% ex-FX), including $128 million of early Qlex (subcutaneous) sales - Winrevair (pulmonary arterial hypertension) sales of $525 million, up 88% - Animal Health sales of $1.8 billion, up 13% - Full-year guidance raised: sales of $65.8–$67.0 billion and non-GAAP EPS of $5.04–$5.16 (ex-Terns)
Management's tone on the Q1 call was confident, with CEO Rob Davis noting the company was "moving with speed to transform our portfolio to one with a diversified set of growth drivers across a broad set of therapeutic areas," and CFO Caroline Litchfield flagging that Keytruda's Q1 growth benefited from ~$250 million of wholesaler purchase timing that would reverse as a headwind in Q3 — a nuance investors should keep in mind when assessing Q2/Q3 Keytruda trends.
1. Keytruda Qlex ramp. The subcutaneous formulation received a permanent J-code on April 1, and the sell-side is looking for meaningful sequential acceleration. Following implementation of a permanent reimbursement code in April, BMO Capital analyst Evan Seigerman projects second-quarter Qlex sales of $363 million, above the consensus estimate of $334 million. Any upside here supports the bull case that Merck can smoothly transition patients to a formulation that extends commercial exclusivity dynamics even as IV Keytruda approaches its 2028 patent cliff.
2. Lipfendra (enlicitide) launch trajectory. Merck's newly approved oral PCSK9 inhibitor is arguably the most important new-product story of the summer. Lipfendra, which won FDA approval in July and is priced at $315 for a 30-day supply, could reshape the cholesterol-lowering market if it overcomes concerns about dosing restrictions. This is viewed as one of the key franchises meant to help offset Keytruda's eventual patent-cliff decline, with some analysts projecting peak sales as high as $5 billion. Expect management to give an early read on scripts/uptake, even though the launch is still in its first weeks.
3. Oncology pipeline momentum beyond Keytruda. The ADC/sac-TMT story continues to develop: sacituzumab tirumotecan, a TROP2-directed antibody-drug conjugate partnered with Kelun-Biotech, met its primary endpoint in a Phase III trial for lung cancer, adding to earlier data published in The Lancet. Analysts at BofA Securities see potential for $2 billion to $4 billion in incremental peak sales from the asset. This directly addresses investor concern about Keytruda's eventual relapse-driven ceiling, since Merck is positioning combination ADC/immunotherapy regimens (with sac-TMT and Padcev) as the next standard of care.
4. Winrevair and cardiometabolic/respiratory momentum. Continued triple-digit-adjacent growth is expected, plus updates on the CADENCE-driven push into a broader heart-failure population (CpcPH-HFpEF) and enlicitide's National Priority Voucher review progress.
5. HIV franchise re-rating. One day before earnings, Merck hosted an investor call around the AIDS 2026 conference in Rio, unveiling positive Phase 3 data (ISLEND-1/2) for once-weekly oral islatravir + lenacapavir (with Gilead) — potentially the first once-weekly oral HIV treatment regimen — alongside a monthly oral PrEP candidate and the recently launched IDVYNSO. Management framed a combined, non-risk-adjusted opportunity of "greater than $5 billion" by the mid-2030s across this HIV portfolio. While this is a longer-duration story, it reinforces the "20-plus new launches" diversification narrative management has been selling since Q1, and should get incremental airtime on tomorrow's call.
6. Gardasil and legacy drag. The vaccine franchise remains a headwind: Q1 Gardasil sales fell 19% (22% ex-FX) on weak China/Japan demand and U.S. public-sector purchasing patterns, and Januvia/Janumet continue to erode on generic competition. Investors should watch whether the China/Gardasil trend has stabilized or is still deteriorating, since this remains the single biggest year-over-year revenue drag in the portfolio.
Healthcare giants Pfizer and Merck are scheduled to report their quarterly earnings on Tuesday, with analysts expecting a decline in their bottom lines, but the framing for Merck specifically is that Merck delays the Keytruda patent cliff and has new approvals in cardiometabolic and oncology areas — i.e., the market is treating this print less as a "beat the number" event and more as a checkpoint on whether the post-Keytruda diversification strategy (Winrevair, Lipfendra, Qlex, HIV, Animal Health, oncology combos) is tracking to plan.
Merck has a strong recent history of beating depressed consensus numbers: for the last reported quarter, it was expected that Merck would post a loss of $1.51 per share when it actually produced a loss of $1.28, delivering a surprise of +15.23%. Over the last four quarters, the company has beaten consensus EPS estimates four times. That beat streak, combined with a history of rarely missing top-line estimates, sets a relatively favorable bar, though the market's own read is mixed — some services flag caution (a "Sell"-leaning quant rank was noted by at least one research shop) even as consensus sell-side ratings skew bullish.
| Metric | Consensus | Q1 2026 Actual | FY2026 Guidance (ex-Terns) |
|---|---|---|---|
| Revenue | ~$16.3–$16.4B (+3–4% YoY) | $16.29B (+5%) | $65.8–$67.0B |
| Non-GAAP EPS | ~-$0.25 to -$0.29 | -$1.28 | $5.04–$5.16 |
| Keytruda family | ~$8.0–8.1B | $8.03B (+12%) | — |
| Keytruda Qlex | ~$334–363M (est.) | $128M | — |
Regardless of tomorrow's print, several near-term regulatory events matter for the stock: - Aug 17, 2026 — PDUFA date for Keytruda/Keytruda Qlex + Padcev in muscle-invasive bladder cancer (based on KEYNOTE-B15) - Oct 4, 2026 — PDUFA date for Welireg + Lenvima in advanced RCC (LITESPARK-011) - Oct 10, 2026 — PDUFA date for ifinatamab deruxtecan (I-DXd) in small-cell lung cancer
This is a "look past the headline loss" quarter. The GAAP/non-GAAP EPS miss-to-prior-year is a known, self-inflicted artifact of the Terns and Cidara deals rather than a sign of operational deterioration. The real questions investors should have answered on the call are: (1) is Keytruda Qlex converting IV volumes fast enough to matter, (2) is Lipfendra's early launch trajectory tracking toward the multi-billion-dollar bull case, (3) does management reaffirm/raise full-year guidance now that Terns has closed, and (4) is there any incremental color on the HIV once-weekly/monthly-PrEP portfolio economics unveiled just one day earlier. With shares already up double digits YTD and trading close to the average analyst price target, the stock's reaction is likely to hinge more on forward commentary and pipeline read-throughs than on the backward-looking, charge-distorted EPS line.